HIPPUTOPE Drug Patent Profile
✉ Email this page to a colleague
When do Hipputope patents expire, and what generic alternatives are available?
Hipputope is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in HIPPUTOPE is iodohippurate sodium i-131. Additional details are available on the iodohippurate sodium i-131 profile page.
Summary for HIPPUTOPE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Patent Applications: | 86 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HIPPUTOPE at DailyMed |
US Patents and Regulatory Information for HIPPUTOPE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | HIPPUTOPE | iodohippurate sodium i-131 | INJECTABLE;INJECTION | 015419-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |